S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Will NIO Partake In China's Economic Awakening?
66,000% upside on tiny biotech? (Ad)
How to Choose a Brokerage Account or Online Broker
Tax Software Specialist Vertex In Buy Zone After Base Breakout
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
What is a Mutual Fund? How Does it Work?
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Will NIO Partake In China's Economic Awakening?
66,000% upside on tiny biotech? (Ad)
How to Choose a Brokerage Account or Online Broker
Tax Software Specialist Vertex In Buy Zone After Base Breakout
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
What is a Mutual Fund? How Does it Work?
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Will NIO Partake In China's Economic Awakening?
66,000% upside on tiny biotech? (Ad)
How to Choose a Brokerage Account or Online Broker
Tax Software Specialist Vertex In Buy Zone After Base Breakout
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
What is a Mutual Fund? How Does it Work?
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Will NIO Partake In China's Economic Awakening?
66,000% upside on tiny biotech? (Ad)
How to Choose a Brokerage Account or Online Broker
Tax Software Specialist Vertex In Buy Zone After Base Breakout
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
What is a Mutual Fund? How Does it Work?
Will Plug Power’s Deal With Energy Vault Move The Needle? 
NASDAQ:ABUS

Arbutus Biopharma (ABUS) Stock Forecast, Price & News

$2.48
-0.06 (-2.36%)
(As of 06/9/2023 ET)
Compare
Today's Range
$2.48
$2.56
50-Day Range
$2.47
$3.06
52-Week Range
$1.85
$3.14
Volume
484,007 shs
Average Volume
457,085 shs
Market Capitalization
$412.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Arbutus Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
141.9% Upside
$6.00 Price Target
Short Interest
Bearish
2.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Arbutus Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.44) to ($0.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

921st out of 987 stocks

Pharmaceutical Preparations Industry

439th out of 466 stocks


ABUS stock logo

About Arbutus Biopharma (NASDAQ:ABUS) Stock

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABUS Stock News Headlines

Arbutus Biopharma (NASDAQ: ABUS)
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Arbutus (ABUS) Upgraded to Buy: Here's Why
Q1 2023 Arbutus Biopharma Corp Earnings Call
Arbutus Biopharma (ABUS) Gets a Buy from Chardan Capital
Arbutus Biopharma (ABUS) to Release Earnings on Thursday
H.C. Wainwright Sticks to Its Buy Rating for Arbutus Biopharma (ABUS)
See More Headlines

ABUS Price History

ABUS Company Calendar

Last Earnings
11/04/2021
Today
6/10/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABUS
Employees
85
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+141.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-69,460,000.00
Net Margins
-211.41%
Pretax Margin
-211.41%

Debt

Sales & Book Value

Annual Sales
$39.02 million
Book Value
$0.91 per share

Miscellaneous

Free Float
157,163,000
Market Cap
$412.00 million
Optionable
Optionable
Beta
2.25

Social Links


Key Executives

  • William H. Collier
    President, Chief Executive Officer & Director
  • Michael J. McElhaugh
    Chief Operating Officer
  • David C. Hastings
    Chief Financial & Accounting Officer
  • Michael J. Sofia
    Chief Scientific Officer
  • Elizabeth Howard
    Secretary, Chief Compliance Officer & Executive VP













ABUS Stock - Frequently Asked Questions

Should I buy or sell Arbutus Biopharma stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABUS shares.
View ABUS analyst ratings
or view top-rated stocks.

What is Arbutus Biopharma's stock price forecast for 2023?

3 Wall Street research analysts have issued 12 month price targets for Arbutus Biopharma's stock. Their ABUS share price forecasts range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 141.9% from the stock's current price.
View analysts price targets for ABUS
or view top-rated stocks among Wall Street analysts.

How have ABUS shares performed in 2023?

Arbutus Biopharma's stock was trading at $2.33 at the beginning of 2023. Since then, ABUS stock has increased by 6.4% and is now trading at $2.48.
View the best growth stocks for 2023 here
.

When is Arbutus Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ABUS earnings forecast
.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) released its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, meeting the consensus estimate of ($0.24). The biopharmaceutical company earned $3.34 million during the quarter, compared to the consensus estimate of $2.36 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 48.34% and a negative net margin of 211.41%. During the same period in the previous year, the firm earned ($0.27) earnings per share.

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.09%), Whitefort Capital Management LP (4.51%), Rubric Capital Management LP (2.53%), Hudson Bay Capital Management LP (1.65%), Geode Capital Management LLC (1.38%) and State Street Corp (1.24%).
View institutional ownership trends
.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $2.48.

How much money does Arbutus Biopharma make?

Arbutus Biopharma (NASDAQ:ABUS) has a market capitalization of $412.00 million and generates $39.02 million in revenue each year. The biopharmaceutical company earns $-69,460,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The official website for the company is www.arbutusbio.com. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at ir@arbutusbio.com, or via fax at 604-419-3201.

This page (NASDAQ:ABUS) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -